Collects long-term data and samples from men with prostate cancer
Collects long-term data and samples from men with high-risk or spreading prostate cancer.
Key facts
- Who runs it
- Radboud University Medical Center
- Where
- Nijmegen, NetherlandsSee the site
- Trial code
- NCT07560748
- NL-OMON58526
- Registry title
- Prospective Prostate Cancer Infrastructure
- Status
- Recruiting
- People taking part
- 700 people, planned
- Started
- 1 Sept 2026
- Expected to end
- Sept 2030
- Type of study
- Observational
- Record updated
- 10 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 18 or older with high-risk localized prostate cancer, or prostate cancer that had already spread when it was found. It collects data and samples over a long time.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- High-risk localized prostate cancer (PSA > 20 ng/mL, ISUP Grade Group 4 or 5, or clinical stage ≥ T2c), or metastatic prostate cancer confirmed by imaging or by biopsy of a metastatic lesion. Mainly prostate adenocarcinoma; adenocarcinoma with mixed small- or large-cell neuroendocrine features is also allowed.
Main reasons for not taking part
- Not currently living in the Netherlands
- Cannot understand Dutch, English, Arabic or Turkish well enough
- No written informed consent
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Diagnosis of either: high-risk localized prostate cancer (any of the following: PSA > 20 ng/mL, ISUP Grade Group 4 or 5, or clinical stage ≥ T2c); or metastatic prostate cancer confirmed by imaging (CT, bone scintigraphy, PSMA PET/CT, or (whole-body) MRI in combination with tumor markers (PSA)), or by biopsy of a metastatic lesion histopathologically deemed to be of prostatic origin
- Prostate adenocarcinoma (our main focus). We will allow the inclusion of adenocarcinoma with mixed small- or large-cell neuroendocrine prostate
- Age ≥ 18 years at the time of inclusion
- Written informed consent
- Able to understand one of the following languages sufficiently: Dutch, English, Arabic or Turkish
Who cannot take part
- Not currently living in the Netherlands
Where in Netherlands
- Radboud University Medical CenterNijmegen, NetherlandsContact: Niven Mehra, PhDTaking people
About the trial
What the trial wants to find out
The goal of this observational study is to collect detailed long-term real-world data and biomaterials from men with high-risk localized prostate cancer and synchronous metastatic hormone-sensitive prostate cancer. This will help to better understand how these patients are treated in daily practice, how treatments affect quality of life, and facilitate biomarker discovery. The infrastructure is also designed to enable future cohort multiple randomized controlled trials.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prospective Prostate Cancer Infrastructure
- Plain-language title
- Collects long-term data and samples from men with prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 10 September 2026